Pegunigalsidase alfa not checked
Chiesi Farmaceutici S.p.A. · Protalix · PRX-102
FollowEvery change as it happens, and a Monday email
Trials
2 active
8 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Fabry Disease (2 trials)
- Main trialPhase 2/3
- “The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.”In the company’s words, NCT05710692 on ClinicalTrials.gov
- Other names
- PRX-102 · Recombinant human alpha galactosidase-A
Other drugs for Fabry Disease
- Migalastat HClAmicus Therapeutics · Phase 3
- LucerastatIdorsia Pharmaceuticals Ltd. · Phase 3
- Agalsidase betaSanofi · Phase 3
- GZ/SAR402671Sanofi · Phase 3
- AMT-191UniQure Biopharma B.V. · Phase 1/2
- EXG110Guangzhou Jiayin Biotech Ltd · Phase 1/2
Coming up2
- Oct 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Oct 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Oct 2027 | Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease | |
| Phase 2/3Recruiting | Oct 2028 | A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease | |
| Phase 3Completed | 17 Dec 2019 | Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) | |
| Phase 3Completed | Oct 2021 | Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function | |
| Phase 3Completed | 21 Jan 2025 | Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease | |
| Phase 3Completed | 13 Apr 2026 | Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients | |
| Phase 1/2Completed | 6 Mar 2016 | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients | |
| Phase 1/2Completed | 26 Aug 2020 | Extension Study of PRX-102 for up to 60 Months |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026